GIST Registry
Authors:
A. Jurečková; I. Kocáková; R. Vyzula
Authors‘ workplace:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in:
Klin Onkol 2012; 25(2): 135-138
Category:
Reports from Clinical Registries
Sources
1. Demetri GD, Benjamin R, Blanke CD et al. NCCN Task Force Report : Optimal management of patients with gastrointestinal stromal tumor (GIST). Expansion and Update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw 2004; 2: S1–S26.
2. Demetri G, van Oosterom A, Garrett C et al. Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. Gastrointestinal Cancers Symposium 2006.
3. Casali PG, Garrett CR, Blackstein ME et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006; 24(18 Suppl): 9513.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2012 Issue 2
Most read in this issue
- Agressive Fibromatosis: Genetic and Biological Correlations
- Aggressive Fibromatosis: Clinical Aspects
- Palliative Surgical Treatment of Tumors of Pancreas and Periampullary Region
- Thyroid Disorders in Women with Breast Cancer